Streetbeat News

Price Targets

ARGX

Stifel analyst Alex Thompson has reaffirmed a Buy rating on argenx (NASDAQ:ARGX) and increased the price target from $557 to $560, indicating a positive outlook on the stock.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 2:25 pm

ACRS

Stifel analyst Alex Thompson has maintained a Hold rating on Aclaris Therapeutics (NASDAQ:ACRS) but has lowered the price target from $2 to $1.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 2:22 pm

ACAD

Stifel analyst Paul Matteis has maintained a Hold rating on ACADIA Pharmaceuticals (NASDAQ:ACAD) and increased the price target from $25 to $27.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 2:20 pm

UTZ

Piper Sandler analyst Michael Lavery has maintained an Overweight rating on Utz Brands (NYSE:UTZ) and increased the price target from $17 to $18. This suggests a positive outlook on the company's stock performance.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 2:16 pm

TRUP

Piper Sandler analyst John Barnidge has maintained a Neutral rating on Trupanion (NASDAQ:TRUP) and increased the price target from $28 to $33.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 2:14 pm

ACNB

Piper Sandler analyst Justin Crowley has maintained a Neutral rating on ACNB Corporation (NASDAQ:ACNB) and increased the price target from $43 to $49.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 2:11 pm

FG

Stephens & Co. analyst John Campbell has maintained an Equal-Weight rating on F&G Annuities & Life (NYSE:FG) and increased the price target from $36 to $47.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 2:09 pm

CVKD

Noble Capital Markets analyst Robert LeBoyer has initiated coverage on Cadrenal Therapeutics with an Outperform rating and set a price target of $4. The company is listed on NASDAQ under the ticker CVKD.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 2:09 pm

UTZ

RBC Capital analyst Nik Modi has maintained an Outperform rating on Utz Brands (NYSE:UTZ) and increased the price target from $17 to $19.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 2:07 pm

ZION

Goldman Sachs analyst Ryan Nash has maintained a Neutral rating on Zions Bancorp (NASDAQ:ZION) and increased the price target from $37 to $42.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 2:05 pm